Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.

OBJECTIVE Several composite scores are available to assess the activity of rheumatoid arthritis (RA). Criteria for remission and active RA based on these continuous scores are important for use in clinical practice and clinical trials. We aimed to reevaluate or to define such criteria for the Disease Activity Score in 28 joints (DAS28) and the Simplified Disease Activity Index (SDAI). METHODS We sampled patient profiles from an observational RA database that included clinical and laboratory variables. Thirty-five rheumatology experts classified these profiles into 1 of 4 categories: remission, low, moderate, or high disease activity. Cutoff values were estimated by mapping scores on the DAS28 and SDAI to these ratings, and analyses of agreement (kappa statistics) and a diagnostic testing approach (receiver operating characteristic curves) were used to validate the estimates. The final criteria were validated using 2 observational cohorts (a routine cohort of 767 patients and an inception cohort of 91 patients). RESULTS Results from the 3 analyses were very similar and were integrated. The criteria for separating remission, low, moderate, and high disease activity based on the SDAI were scores of 3.3, 11, and 26, respectively; those based on the DAS28 were scores of 2.4, 3.6, 5.5, respectively. In the routine cohort, these cutoff values showed substantial agreement (weighed kappa = 0.70) and discriminated between groups of patients with clearly different functional capacities (P < 0.001). In the inception cohort, these cutoff scores differentiated responders (those with a 20% response on the American College of Rheumatology improvement criteria) from nonresponders (P < 0.01), as well as patients with and without radiologic progression (P < 0.05). CONCLUSION New criteria for levels of RA disease activity were determined and internally validated. These criteria, which are based on current and explicit expert judgment, are valuable in this era of rapidly advancing therapeutic approaches.

[1]  A. Zwinderman,et al.  Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. , 2002, Arthritis and rheumatism.

[2]  D. Heijde,et al.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. , 1992 .

[3]  M. Prevoo,et al.  Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. , 1996, British journal of rheumatology.

[4]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[5]  J. Smolen,et al.  Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: New aspects after the fall of the pyramid and the rise of new therapeutics , 2003, Current Rheumatology Reports.

[6]  P. Emery,et al.  Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. , 2003, Clinical and experimental rheumatology.

[7]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[8]  P. Riel,et al.  Clinical outcome measures in rheumatoid arthritis , 2000 .

[9]  J. Hazes,et al.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. , 2000, Arthritis and rheumatism.

[10]  J. Smolen,et al.  The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. , 2002, Rheumatology.

[11]  H. Holman,et al.  Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.

[12]  D M Chaput de Saintonge,et al.  Clinical judgment in rheumatoid arthritis. I. Rheumatologists' opinions and the development of 'paper patients'. , 1983, Annals of the rheumatic diseases.

[13]  J. Smolen.  The work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT) , 1992, British journal of rheumatology.

[14]  P. Emery,et al.  Early rheumatoid arthritis: time to aim for remission? , 1995, Annals of the rheumatic diseases.

[15]  M. A. van 't Hof,et al.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. , 1990, Annals of the rheumatic diseases.

[16]  A. Silman,et al.  Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. , 2003, Arthritis and rheumatism.

[17]  H. Paulus.  Defining remission in rheumatoid arthritis: what is it? Does it matter? , 2004, The Journal of rheumatology.

[18]  Maarten Boers,et al.  The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. , 2004, Arthritis and rheumatism.

[19]  J. Smolen,et al.  Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. , 2002, The Journal of rheumatology.

[20]  J. Smolen,et al.  Therapeutic strategies for rheumatoid arthritis , 2003, Nature Reviews Drug Discovery.

[21]  A. Zwinderman,et al.  Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. , 2001, The American journal of medicine.

[22]  M. Uffmann,et al.  Patients and Methods , 2022 .

[23]  T. Pincus,et al.  Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[24]  A. Larsen,et al.  Radiographic Evaluation of Rheumatoid Arthritis and Related Conditions by Standard Reference Films , 1977, Acta radiologica: diagnosis.

[25]  J. Smolen,et al.  Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey , 2004, Annals of the rheumatic diseases.

[26]  L. Kiemeney,et al.  The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[27]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[28]  M. Pepys,et al.  Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. , 1982, The Journal of rheumatology.

[29]  T. Pincus,et al.  A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. , 2003, Clinical and experimental rheumatology.

[30]  M. V. van Leeuwen,et al.  The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. , 1993, British journal of rheumatology.

[31]  D. Mitchell,et al.  Preliminary criteria for clinical remission in rheumatoid arthritis. , 1981, Arthritis and rheumatism.

[32]  A. van der Heide,et al.  The Effectiveness of Early Treatment with Second-Line Antirheumatic Drugs , 1996, Annals of Internal Medicine.

[33]  S. van der Linden,et al.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis , 1997, The Lancet.

[34]  P. Tugwell,et al.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice. , 2003, Rheumatology.

[35]  Rene Westhovens,et al.  COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. , 2002, Arthritis and rheumatism.

[36]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[37]  Maarten Boers,et al.  Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. , 2004, Arthritis and rheumatism.

[38]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[39]  Jacob Cohen,et al.  Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. , 1968 .

[40]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[41]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[42]  D. M. van der Heijde,et al.  Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.

[43]  M. V. van Leeuwen,et al.  Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. , 1998, British Journal of Rheumatology.